All In Biotech

Drug Trial Radar · NCT07911124

Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease

A Randomized Double-Blind Placebo-Controlled Phase II Clinical Trial to Investigate the Effect of Platelet Inhibition With Ticagrelor to Reduce Inflammation and Surrogate Cardiovascular Markers in Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Dec 2030

Study completion Jul 2031

Sponsor

Lead sponsor
University of ArkansasAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Nov 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if treatment with ticagrelor tablets can decrease inflammation in patients with Chronic Kidney Disease (CKD). Inflammation is thought to contribute to the risk of heart disease which is the leading cause of death in patients with CKD. Decreasing inflammation may decrease the risk of heart disease. The main questions it aims to answer are: * Why are patients with CKD at increased risk for heart disease and how to reduce that risk in the future. * If there could be new treatment options for managing inflammation in blood of patients with CKD. Researchers will compare Ticagrelor to a Placebo (a look-alike substance that contains no drug) to see if ticagrelor decreases inflammation in adult patients with CKD. A comparator (control) group not receiving the drug/placebo will consist of adults without CKD. Participants with CKD will: * Take ticagrelor 90 mg or placebo orally twice daily for 42 days * Visit the clinic once every 2 weeks for checkups, tests, and bloodwork * Participation will last approximately 12 weeks Participants without CKD (control group) will visit the clinic twice (7 weeks apart) to provide information and bloodwork. Participation will last approximately 7 weeks with additional optional visits.

Conditions

  • Chronic Kidney Disease (CKD)

Interventions

  • Ticagrelor: an oral, direct-acting, reversibly binding P2Y12 receptor antagonistDrug

    Ticagrelor 90 mg orally twice daily for 42 days

  • PlaceboDrug

    Placebo orally twice daily for 42 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Aim 1: post-treatment IL-1β valueTime frame: from baseline (day 0) to post-treatment (day 42)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.